Publications by authors named "Yu-Waye Chu"

Claim this Profile
M
Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling.
Iraj Hosseini, Kapil Gadkar, Eric Stefanich, Chi-Chung Li, Liping L Sun, Yu-Waye Chu

NPJ Syst Biol Appl· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).
Franck Morschhauser, Ian W Flinn, Ranjana Advani, Laurie H Sehn, Catherine Diefenbach, Yu-Waye Chu

Lancet Haematol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of Correlation Between Early and Late Efficacy Endpoints to Identify Potential Surrogacy Relationships in Non-Hodgkin Lymphoma: a Literature-Based Meta-analysis of 108 Phase II and Phase III Studies.
Rui Zhu, Dan Lu, Yu-Waye Chu, Akiko Chai, Michelle Green

AAPS J· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.
Ranjana H Advani, Daniel Lebovic, Andy Chen, Mark Brunvand, Andre Goy, Yu-Waye Chu

Clin Cancer Res· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia.
Steven R Leong, Siddharth Sukumaran, Maria Hristopoulos, Klara Totpal, Shannon Stainton, Yu-Waye Chu

Blood· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Maria Corinna A Palanca-Wessels, Myron Czuczman, Gilles Salles, Sarit Assouline, Laurie H Sehn, Yu-Waye Chu

Lancet Oncol· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.
Liping L Sun, Diego Ellerman, Mary Mathieu, Maria Hristopoulos, Xiaocheng Chen, Yu-Waye Chu

Sci Transl Med· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma.
Dongwei Li, Kirsten Achilles Poon, Shang-Fan Yu, Randall Dere, MaryAnn Go, Josefa Chuh, Yu-Waye Chu

Mol Cancer Ther· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
Sara A Hurvitz, Luc Dirix, Judit Kocsis, Giulia V Bianchi, Janice Lu, Chunyan Song, Yu-Waye Chu

J Clin Oncol· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia.
Yu-Waye Chu, Andrew Polson

Future Oncol· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Trastuzumab Emtansine (T-DM1) on QT Interval and Safety of Pertuzumab Plus T-DM1 in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Manish Gupta, Bei Wang, Timothy J Carrothers, Patricia M LoRusso, Yu-Waye Chu

Clin Pharmacol Drug Dev· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer.
Brendan C Bender, Franziska Schaedeli-Stark, Reinhold Koch, Amita Joshi, Yu-Waye Chu

Cancer Chemother Pharmacol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer.
Dan Lu, Howard A Burris, Bei Wang, E Claire Dees, Javier Cortes, Yu-Waye Chu

Curr Drug Metab· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism.
Ben-Quan Shen, Daniela Bumbaca, Ola Saad, Qin Yue, Cinthia V Pastuskovas, Yu-Waye Chu

Curr Drug Metab· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer.
Manish Gupta, Patricia M Lorusso, Bei Wang, Joo-Hee Yi, Howard A Burris, Yu-Waye Chu

J Clin Pharmacol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer.
Sandhya Girish, Manish Gupta, Bei Wang, Dan Lu, Ian E Krop, Yu-Waye Chu

Cancer Chemother Pharmacol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
Howard A Burris, Hope S Rugo, Svetislava J Vukelja, Charles L Vogel, Rachel A Borson, Yu-Waye Chu

J Clin Oncol· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exogenous insulin-like growth factor 1 enhances thymopoiesis predominantly through thymic epithelial cell expansion.
Yu-Waye Chu, Sabrina Schmitz, Baishakhi Choudhury, William Telford, Veena Kapoor

Blood· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CCL25 increases thymopoiesis after androgen withdrawal.
Kirsten M Williams, Philip J Lucas, Catherine V Bare, Jiun Wang, Yu-Waye Chu

Blood· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Murine models of chronic graft-versus-host disease: insights and unresolved issues.
Yu-Waye Chu, Ronald E Gress

Biol Blood Marrow Transplant· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dysregulation of IL-15-mediated T-cell homeostasis in TGF-beta dominant-negative receptor transgenic mice.
Philip J Lucas, Seong-Jin Kim, Crystal L Mackall, William G Telford, Yu-Waye Chu

Blood· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Flt3 ligand enhances thymic-dependent and thymic-independent immune reconstitution.
Terry J Fry, Manoj Sinha, Matthew Milliron, Yu-Waye Chu, Veena Kapoor

Blood· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exogenous IL-7 increases recent thymic emigrants in peripheral lymphoid tissue without enhanced thymic function.
Yu-Waye Chu, Sarfraz A Memon, Susan O Sharrow, Frances T Hakim, Michael Eckhaus

Blood· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis